Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m + 88BV59H21-2V67-66
- Development stage
- Unknown
- Lead developer
- Corixa
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Technetium Tc 99m + 88BV59H21-2V67-66 is a radiopharmaceutical combination consisting of the radioisotope technetium Tc 99m and a totally human monoclonal antibody known as 88BV59H21–2V67–66 (also referred to as HumaSPECT-Tc). The antibody targets tumor-associated antigens, enabling specific binding to cancer cells. When labeled with technetium Tc 99m, this agent is used for immunoscintigraphy—an imaging technique that allows for the detection and localization of tumors, particularly in colorectal cancer patients. The mechanism involves the antibody binding to tumor cell surface antigens; the attached radioactive isotope emits gamma radiation detectable by imaging equipment, thus highlighting areas of tumor involvement. This approach aids in staging disease and assessing metastases[3][4][6].
- Brand names
- OncoSPECT/CR ColorectalHumaSPECT-Tc
- Other names
- technetium Tc 99m + HumaSPECT-Tctechnetium Tc 99m + human monoclonal antibody 88BV59H21-2V67-66
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on technetium Tc 99m + 88BV59H21-2V67-66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m + 88BV59H21-2V67-66.